Do the current performance-based schemes in Italy really work? "Success fee": A novel measure for cost-containment of drug expenditure

Value in Health

Volumn 18, Issue 1, 2015, Pages 131-136

  Navarria, Andrea ^a   Drago, Valentina ^b   Gozzo, Lucia ^a   Longo, Laura ^c   Mansueto, Silvana ^c   Pignataro, Giacomo ^a   Drago, Filippo ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^c UNIVERSITY OF CATANIA   (Italy)

Author keywords

cost containment; performance based; reimbursement; risk sharing

Indexed keywords

AZACITIDINE; BEVACIZUMAB; BORTEZOMIB; BRENTUXIMAB VEDOTIN; CATUMAXOMAB; CETUXIMAB; DASATINIB; ERIBULIN; ERLOTINIB; EVEROLIMUS; LAPATINIB; LENALIDOMIDE; MESYLIC ACID; NILOTINIB; OFATUMUMAB; PANITUMUMAB; PAZOPANIB; PEGAPTANIB; PLERIXAFOR; RANIBIZUMAB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TRABECTEDIN; TRASTUZUMAB; VINFLUNINE;

ARTICLE; BUDGET; COST CONTROL; DRUG COST; DRUG INDUSTRY; HUMAN; ITALY; PRIORITY JOURNAL; PUBLIC HEALTH; REIMBURSEMENT; UNITED KINGDOM; ECONOMICS; HEALTH CARE COST; TRENDS;

COST CONTROL; DRUG COSTS; HEALTH EXPENDITURES; HUMANS; ITALY; REIMBURSEMENT, INCENTIVE;

EID: 84920846416     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2014.09.007     Document Type: Article

References (16)

1. J. Adamski, B. Godman, and G. Ofierska-Sujkowska Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers. BMC Health Serv Res 10 2010 153
2. C. McCabe, L. Bergmann, and N. Bosanquet Market and patient access to new oncology products in Europe: a current, multidisciplinary perspective Ann Oncol 20 2009 403 412
3. C.E. Reeder, and D. Gordon Managing oncology costs Am J Manag Care 12 Suppl. 2006 S3 16 quiz S17-9
4. R. Sullivan, J. Peppercorn, and K. Sikora Delivering affordable cancer care in high-income countries Lancet Oncol 12 2011 933 980
5. T. Fojo, and C. Grady How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question J Natl Cancer Inst 101 2009 1044 1048
6. E. Nadler, B. Eckert, and P.J. Neumann Do oncologists believe new cancer drugs offer good value? Oncologist 11 2006 90 95
7. Experts in Chronic Myeloid Leukemia The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts Blood 121 2013 4439 4442
8. H.M. Guirgis Proposal for a novel methodology to screen and score cost versus survival for anticancer drugs in metastatic disease: could cost weigh in evaluation? J Oncol Pract 8 2012 224 230
9. L.P. Garrison Jr, A. Towse, and A. Briggs Performance-based risk-sharing arrangements - good practices for design, implementation, and evaluation: report of the ISPOR Good Practices for Performance-Based Risk-Sharing Arrangements Task Force Value Health 16 2013 703 719
10. Espín J, Rovira J, García L. Experiences and Impact of European Risk-Sharing Schemes Focusing on Oncology Medicines. Granada, Spain: European Medicines Information Network (EMINET), Andalusian School of Public Health, 2011.
11. A. Towse, and L.P. Garrison Jr Can't get no satisfaction? Will pay for performance help? Toward an economic framework for understanding performance-based risk-sharing agreements for innovative medical products Pharmacoeconomics 28 2010 93 102
12. J.J. Carlson, S.D. Sullivan, and L.P. Garrison Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers Health Pol 96 2010 179 190
13. Drug Use in Italy: National Report 2012. Rome, Italy: Osservatorio nazionale sullimpiego dei Medicinali (OsMed) - Agenzia Italiana del Farmaco, 2013.
14. P. Russo, F.S. Mennini, P.D. Siviero, and G. Rasi Time to market and patient access to new oncology products in Italy: a multistep pathway from European context to regional health care providers Ann Oncol 21 2010 2081 2087
15. IMS Health. Italy, 2013.
16. L.M. Ellis, D.S. Bernstein, E. Voest, and J. Berlin American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes J Clin Oncol 32 2014 1277 1280